ClearPoint Neuro (CLPT) AI Stock Analysis

• Market Cap: $518.23M
• Dividend Yield: N/A
• Average Volume (3M): 1.13M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.57
• Revenue Growth: 12.83%
• EPS Growth: -19.53%
• Country: US
• Employees: 115
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.21
• Shares Outstanding: 28,427,418
• 10 Day Avg. Volume: 1,227,886
• 30 Day Avg. Volume: 1,129,965
• PEG Ratio: 0.99
• Price to Book (P/B): 16.37
• Price to Sales (P/S): 13.24
• P/FCF Ratio: -45.06
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $30.00
• Price Target Upside: 9.81% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: $20.00 ▼(-26.79% Downside)

ClearPoint Neuro's overall stock score is driven by strong revenue growth and strategic expansions, as highlighted in the earnings call. However, ongoing profitability challenges and bearish technical indicators weigh down the score. The company's solid cash position and partnerships provide a foundation for future growth, but immediate financial performance and valuation concerns remain.

Positive Factors

Revenue Growth

Consistent revenue growth across all segments indicates strong market demand and effective business strategies, supporting long-term expansion.

Global Expansion

Global expansion and regulatory clearances in 36 countries enhance market reach and competitive positioning, driving sustainable growth.

Strategic Acquisition

The acquisition of Irras Holdings expands product offerings and customer base, potentially increasing revenue and market share in the long term.

Negative Factors

Profitability Challenges

Ongoing losses and negative profit margins indicate operational inefficiencies, posing risks to financial sustainability and investor confidence.

Increased Operating Expenses

Rising operating expenses, driven by R&D and personnel costs, could pressure margins and delay profitability improvements, affecting long-term growth.

Negative Operating Cash Flow

Negative operating cash flow suggests reliance on external funding, which may limit financial flexibility and increase risk during economic downturns.

ClearPoint Neuro Business Overview & Revenue Model

Company Description

ClearPoint Neuro, Inc. is a medical technology company focused on developing and commercializing innovative solutions for the treatment of neurological disorders. The company operates primarily in the healthcare sector, specializing in neurosurgical devices and related services. ClearPoint's core product is its ClearPoint Neuro Navigation System, which enables precise targeting of brain structures for therapeutic procedures, including drug delivery and biopsy. Additionally, the company is involved in advancing its technology through strategic collaborations and clinical trials aimed at improving patient outcomes in neurosurgery.

How the Company Makes Money

ClearPoint Neuro generates revenue through multiple streams, primarily from the sale of its neurosurgical navigation systems and disposables used in procedures. The company's revenue model includes direct sales to hospitals and surgical centers, as well as potential recurring revenue from consumable products associated with its systems. Furthermore, ClearPoint engages in partnerships with pharmaceutical companies for drug delivery applications and collaborates with research institutions for clinical trials, which may also contribute to its income through grants and shared revenue agreements. The company is focused on expanding its market presence and product offerings, which could provide additional revenue opportunities in the growing field of neurosurgery.

ClearPoint Neuro Financial Statement Overview

Summary

ClearPoint Neuro shows strong revenue growth and a solid balance sheet with low leverage. However, profitability challenges and negative operating cash flow remain significant concerns.

Income Statement

ClearPoint Neuro has shown a consistent increase in revenue over the years, with a notable revenue growth rate of 31% from 2023 to 2024. However, the company continues to operate at a loss with a negative net profit margin of -60.3% in 2024. The gross profit margin remains strong at 60.9%, indicating efficient cost management relative to revenue. The EBIT and EBITDA margins remain negative, reflecting ongoing operational challenges.

Balance Sheet

The company's balance sheet shows improvement in stockholders' equity, which increased to $25.4 million in 2024 from $21.2 million in 2023. The debt-to-equity ratio has improved significantly over the years, standing at 0.14 in 2024, indicating lower leverage risk. The equity ratio is robust at 64.8%, highlighting a strong capital structure. However, the company needs to address its negative net income for better return on equity.

Cash Flow

ClearPoint Neuro's cash flow situation shows a positive trend in free cash flow growth, with free cash flow improving by 37.6% from 2023 to 2024. However, the operating cash flow remains negative, which could impact long-term sustainability. The company has been financing its operations through external funding, as seen in its financing cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	34.33M	31.39M	23.95M	20.55M	16.30M	12.83M
Gross Profit	21.05M	19.12M	13.61M	13.53M	11.29M	9.12M
EBITDA	-21.34M	-17.84M	-20.99M	-15.58M	-12.74M	-4.79M
Net Income	-23.14M	-18.91M	-22.09M	-16.43M	-14.41M	-6.78M
Balance Sheet
Total Assets	60.36M	39.19M	42.66M	55.49M	65.58M	29.52M
Cash, Cash Equivalents and Short-Term Investments	38.22M	20.10M	23.14M	37.49M	54.11M	20.10M
Total Debt	6.54M	3.57M	13.94M	11.99M	12.28M	24.12M
Total Liabilities	44.48M	13.80M	21.49M	18.60M	16.79M	27.14M
Stockholders Equity	15.87M	25.39M	21.17M	36.89M	48.79M	2.38M
Cash Flow
Free Cash Flow	-13.82M	-9.22M	-14.77M	-17.31M	-12.87M	-8.29M
Operating Cash Flow	-13.09M	-8.95M	-13.72M	-16.17M	-12.70M	-7.81M
Investing Cash Flow	-736.00K	-275.00K	8.95M	-10.74M	-168.00K	-482.00K
Financing Cash Flow	30.65M	6.19M	296.00K	409.00K	46.88M	22.69M

ClearPoint Neuro Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 27.32
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLPT, the sentiment is Negative. The current price of 27.32 is above the 20-day moving average (MA) of 23.27, above the 50-day MA of 19.32, and above the 200-day MA of 14.61, indicating a neutral trend. The MACD of -0.96 indicates Positive momentum. The RSI at 34.03 is Neutral, neither overbought nor oversold. The STOCH value of 14.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLPT.

ClearPoint Neuro Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVS	66 Neutral	$624.23M	-1,020.27	4.97%	―	1.58%	―
CLPT	60 Neutral	$518.23M	―	-85.68%	―	12.83%	-19.53%
SIBN	57 Neutral	$655.31M	―	-14.18%	―	22.93%	43.83%
OFIX	52 Neutral	$592.41M	-4.92	-24.60%	―	4.31%	3.26%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AVNS	51 Neutral	$521.28M	―	-46.68%	―	2.70%	-3090.51%
ZIMV	48 Neutral	―	―	-4.76%	―	-19.52%	94.65%

ClearPoint Neuro Corporate Events

ClearPoint Neuro’s Q3 2025: Revenue Growth and Strategic Advances

ClearPoint Neuro, Inc. is a global company specializing in device, cell, and gene therapy navigation for brain and spine procedures, offering both clinical products and preclinical development services. In its third-quarter 2025 earnings report, ClearPoint Neuro highlighted a 9% year-over-year revenue increase to $8.9 million and significant strategic advancements, including the operational launch of its new ClearPoint Advanced Laboratories and the development of a prototype Robotic Neuro-Navigation System. Key financial metrics showed a gross margin increase to 63%, driven by higher service revenue margins and product mix. The company also reported expanded international regulatory approvals and a strategic acquisition agreement with IRRAS Holdings, Inc., aimed at enhancing its presence in the neurocritical care space. Looking ahead, ClearPoint Neuro remains focused on expanding its specialized treatment centers to support cell and gene therapy trials, with expectations of driving double-digit growth in biologics and drug delivery revenue in the coming quarters.

ClearPoint Neuro Announces Merger with IRRAS Holdings

On November 6, 2025, ClearPoint Neuro announced a merger agreement with IRRAS Holdings, Inc., a medical technology company specializing in neurocritical care. This strategic acquisition is expected to expand ClearPoint Neuro’s drug delivery portfolio and add commercial scale across a $0.5 billion market for intracranial bleeding treatment. The merger will provide ClearPoint Neuro access to a large existing market and enhance its operational scale with an expanded commercial team. The combined entity is projected to achieve significant revenue growth, with an estimated total revenue range of $54.0 to $60.0 million for 2026.

The most recent analyst rating on (CLPT) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.

ClearPoint Neuro Reports Q3 Results and Strategic Advances

On November 6, 2025, ClearPoint Neuro reported its third-quarter financial results, highlighting a 9% year-over-year revenue increase to $8.9 million and reaffirming its full-year forecast. The company announced several strategic advancements, including the operational launch of its new pre-clinical CRO facility, FDA clearance for expanded use of its PRISM Laser Therapy System, and a prototype Robotic Neuro-Navigation System. Additionally, ClearPoint Neuro is expanding its international regulatory approvals and has signed an agreement to acquire IRRAS Holdings, Inc., which will broaden its market reach into neurocritical care. These developments are expected to enhance the company’s market position and support its growth strategy across four pillars, including biologics and drug delivery, neurosurgery navigation, laser therapy, and the newly introduced cranial irrigation and aspiration.

The most recent analyst rating on (CLPT) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.

Clearpoint Neuro’s Earnings Call Highlights Growth and Expansion

Clearpoint Neuro, Inc. recently held its earnings call, reflecting a positive sentiment overall. The company reported significant revenue growth and successful product launches, alongside strategic expansions. Despite some challenges with gross margin and operating expenses, Clearpoint’s strong cash position and strategic partnerships are seen as key factors positioning the company for future growth.

ClearPoint Neuro Achieves Record Revenue in Q2 2025

ClearPoint Neuro, Inc. is a global device, cell, and gene therapy-enabling company that specializes in precise navigation to the brain and spine, offering both clinical products and preclinical development services. In its second quarter of 2025, ClearPoint Neuro reported record revenue of $9.2 million, marking a 17% increase from the previous year, alongside a significant cash infusion from financing arrangements. The company’s neurosurgery navigation and therapy revenue saw a notable 33% growth, driven by the success of its SmartFrame® Family Navigation devices and ClearPoint PRISM® Laser Therapy Applicators. Additionally, ClearPoint Neuro entered into a financing agreement with Oberland Capital Management, securing up to $105 million, which bolstered its cash position to $41.5 million by the end of the quarter. Despite the positive revenue growth, the company reported a net loss of $5.8 million, attributed to increased operating expenses and development costs. Looking ahead, ClearPoint Neuro maintains its revenue outlook for 2025 between $36 million and $41 million, as it continues to advance its strategic growth initiatives across multiple sectors.

ClearPoint Neuro Reports Record Q2 Revenue Growth

On August 12, 2025, ClearPoint Neuro reported its second quarter financial results, highlighting a record revenue of $9.2 million, marking a 17% increase from the previous year. The company also secured a substantial cash infusion through a financing arrangement and stock purchase agreement with Oberland Capital Management, enhancing its cash position to $41.5 million. The growth was driven by increased sales in neurosurgery navigation and therapy, particularly from SmartFrame® Family Navigation devices and ClearPoint PRISM® Laser Therapy Applicators. ClearPoint Neuro’s strategic ‘Fast. Forward.’ phase aims to expand its operations across multiple growth vectors, including operating room expansion, laser therapy, regulatory approvals, and partnerships with BioPharma, positioning the company for continued growth and innovation in the industry.

The most recent analyst rating on (CLPT) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.